AngioDynamics(US:ANGO)2021-05-28 19:10Strategic Transformation - AngioDynamics is pursuing larger, faster-growing markets through active portfolio management, relying on technology and innovation to produce measurable patient outcomes[5] - The company is focusing resource development in areas that offer better opportunities for success[6] - Portfolio transformation and strength are driven by R&D, M&A, and Clinical & Regulatory activities[6] - AngioDynamics aims to become a growth company, with a U S Total Addressable Market (TAM) of $7 8 billion by 2025, with a market CAGR of 3-7%[8] Peripheral Atherectomy - AngioDynamics' Auryon system provides access to the peripheral atherectomy market[8] - The Auryon system uses a photon energy of 3 5 eV to vaporize calcium while remaining nonreactive to vessel endothelium[16] - AngioDynamics is expanding commercial and clinical presence, physician training programs, and physician ambassador programs for Peripheral Atherectomy[21] Thrombus Management - AngioVac's current use is focused on the Right Atrium, which is a $77 million addressable market[28] - AlphaVac, a multi-purpose mechanical aspiration device, is planned for launch and will allow AngioDynamics to compete in the broader DVT & PE addressable markets of $3 billion for Pulmonary Embolism and $1 3 billion for Deep Vein Thrombosis[28] - AngioDynamics is developing the next generation of AngioVac, driven by physician requests for use in DVT[30] Irreversible Electroporation (NanoKnife) - In 2020, there were 1,256,970 new cancer cases[44] - Adoption of focal therapy for prostate cancer remains low (<5%) due to gaps within existing technology[51] Financial Performance (Q3 YTD FY2021) - Revenue reached $214 2 million, a 4 1% increase year-over-year[55] - Adjusted EPS was $0 05, compared to $0 15 in the previous year[55]